PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease
Open Access
- 28 March 2023
- journal article
- research article
- Published by Elsevier in JHEP Reports
- Vol. 5 (6) , 100743
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
This publication has 43 references indexed in Scilit:
- The MELD score in patients awaiting liver transplant: Strengths and weaknessesJournal of Hepatology, 2011
- Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver diseaseGut, 2010
- Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis CGut, 2010
- Prognostic Value of Ishak Fibrosis Stage: Findings From the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis TrialHepatology, 2010
- Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assayHepatology, 2008
- Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersHepatology, 2008
- The natural history of hepatitis C with severe hepatic fibrosisJournal of Hepatology, 2007
- Systematic review: the model for end‐stage liver disease – should it replace Child‐Pugh's classification for assessing prognosis in cirrhosis?Alimentary Pharmacology & Therapeutics, 2005
- MELD is not enough—enough of MELD?Journal of Hepatology, 2005
- Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy studyGut, 2004